Welcome to our dedicated page for Dswiss SEC filings (Ticker: DQWS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DSwiss Inc. filings document the public-company status, registrant identity, and governance events of a Nevada corporation associated with DQWS. An 8-K record centers on Item 5.02 disclosure for director and officer matters, including changes in board composition and the concentration of director roles after a resignation.
These regulatory documents provide formal records of material events, corporate signatories, and the governance framework surrounding DSwiss's reporting obligations. The filings complement the company's operating profile in biotech-nutraceutical products, medical consumables, beauty supplies, and OEM/ODM services by recording public-company governance and status disclosures.
DSwiss, Inc. reported sharply weaker Q1 2026 results while flagging serious going concern risks. Revenue for the three months ended March 31, 2026 fell to $477,737 from $1,001,186, cutting gross profit to $159,192. Net income dropped to just $4,291, or $0.0001 per basic and diluted share.
The balance sheet shows $220,027 of cash against total liabilities of $693,393 and a stockholders’ deficit of $5,789. Management reports an accumulated deficit of $1,460,499, negative operating cash flow of $55,119, and explicitly states there is “substantial doubt” about the company’s ability to continue as a going concern without improved profitability or new financing.
DSwiss, Inc. (DQWS) reported a small net loss for 2025 as revenue declined modestly and margins compressed. The company generated $2,920,986 in revenue for the year ended December 31, 2025, down 6.16% from 2024, mainly from OEM/ODM nutraceutical and skincare sales.
Gross profit was $564,562, with gross margin easing to 19.33% from 20.02%. DSwiss moved from a prior-year net profit of $22,223 to a net loss of $76,860, increasing accumulated losses to $1,464,790. Liquidity weakened, with a working capital deficit of $133,691 and cash of $285,034 at year-end, versus prior surplus and higher cash.
The Nevada-based nutraceutical and skincare OEM/ODM operator continues to focus on Asia-Pacific markets while re-entering international markets such as China and the United States. It is investing in R&D, talent expansion and M&A opportunities, while acknowledging material weaknesses in internal controls and outlining remediation plans.
DSwiss, Inc. (DQWS) filed its Q3 2025 10-Q, reporting softer quarterly results and a going concern warning. Q3 revenue was $441,618 versus $1,027,198 a year ago, with a net loss of $97,891 compared to a loss of $61,468 last year. Gross profit for the quarter was $58,569.
For the nine months ended September 30, 2025, revenue reached $2,464,144 and net income was $72,973. Operating cash flow was $(18,597). Cash and cash equivalents were $367,519. Total assets were $800,748 and total liabilities were $652,155, resulting in equity of $148,593. Shares outstanding were 206,904,585 as of September 30, 2025.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern due to accumulated deficit and negative operating cash flow. Customer concentration was high, with one customer accounting for 67% of Q3 revenue. Internal controls were deemed not effective due to material weaknesses. The Company recognized an operating lease right‑of‑use asset of $156,014 following a new office lease commencing March 1, 2025.
DSwiss, Inc. reported a board change, with director Sui Ting Wong resigning on October 1, 2025. Following this resignation, Leong Ming Chia became the company’s sole director. He already serves as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director, concentrating both management and board oversight roles in a single individual. The company also recorded a written consent of the board dated October 1, 2025 to reflect this change.